Clinical Trial Detail

NCT ID NCT03107780
Title MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

glioblastoma multiforme

gliosarcoma

Therapies

AMG 232

Age Groups: adult senior

Additional content available in CKB BOOST